Kymera Therapeutics (NASDAQ:KYMR) Trading Down 6.9% - Should You Sell?

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report)'s stock price fell 6.9% on Wednesday . The stock traded as low as $19.66 and last traded at $19.59. 312,285 shares changed hands during trading, a decline of 42% from the average session volume of 537,310 shares. The stock had previously closed at $21.05.

Wall Street Analyst Weigh In

KYMR has been the subject of several analyst reports. Leerink Partners reissued an "outperform" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. HC Wainwright boosted their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Stephens reiterated an "overweight" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Finally, Citigroup began coverage on Kymera Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $52.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $56.36.

Kymera Therapeutics Stock Up 5.4 %

The company has a market capitalization of $1.65 billion, a P/E ratio of -10.87 and a beta of 2.22. The company's fifty day moving average price is $31.62 and its 200 day moving average price is $39.69.

Remove Ads

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing analysts' consensus estimates of ($0.76) by ($0.12). The company had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Research analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Ellen Chiniara sold 2,241 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the transaction, the insider now directly owns 80,085 shares in the company, valued at $2,438,588.25. This represents a 2.72 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Jeremy G. Chadwick sold 1,383 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the transaction, the chief operating officer now owns 67,800 shares of the company's stock, valued at $2,064,510. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 10,659 shares of company stock worth $324,567. 15.82% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in KYMR. Blue Trust Inc. raised its position in Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock worth $25,000 after purchasing an additional 270 shares during the last quarter. State of Wyoming bought a new position in shares of Kymera Therapeutics in the fourth quarter valued at $45,000. GF Fund Management CO. LTD. bought a new stake in Kymera Therapeutics during the fourth quarter worth $55,000. KBC Group NV increased its position in shares of Kymera Therapeutics by 53.8% during the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after purchasing an additional 752 shares during the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Kymera Therapeutics by 3,851.5% during the 1st quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock valued at $183,000 after buying an additional 6,509 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.